Clinical PET in oncology

Revista Espanola de Medicina Nuclear

Volumn 19, Issue 3, 2000, Pages 219-224

  Biersack, H J ^a   Bender, H ^a   Ruhlmann, J ^a   Oehr, P ^a   Guhlke, S ^a   Grunwald F ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; GLUCOSE TRANSPORTER; GRANULOCYTE ANTIBODY; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODINE 131; METHIONINE C 11; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OXYGEN; TECHNETIUM 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE MARROW METASTASIS; BRAIN NECROSIS; BRAIN TUMOR; BREAST CANCER; CANCER CELL; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; FOCAL EPILEPSY; GERM CELL TUMOR; GLIOMA; GLUCOSE TRANSPORT; GLYCOLYSIS; HEAD AND NECK CANCER; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDICAL PRACTICE; MEDICARE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DIAGNOSIS; REIMBURSEMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TESTIS CANCER; THYROID CARCINOMA; ULTRASOUND; WHOLE BODY SCINTISCANNING; ANTIBODY SPECIFICITY; ARTIFACT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COOPERATION; CYCLOTRON; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; INFLAMMATION; INSTRUMENTATION; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; NEOPLASM; NUCLEAR MEDICINE; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PRACTICE GUIDELINE; PRIVATE PRACTICE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; UNIVERSITY; UTILIZATION REVIEW;

ARTIFACTS; BLOOD GLUCOSE; COOPERATIVE BEHAVIOR; CYCLOTRONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; GERMANY; HUMANS; INFLAMMATION; LYMPHATIC METASTASIS; MALE; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; NUCLEAR MEDICINE; ORGAN SPECIFICITY; PRACTICE GUIDELINES; PRIVATE PRACTICE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; UNIVERSITIES;

EID: 0034200183     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Biersack HJ, Bender H, Ruhlmann J, Schomburg A, Grünwald F. FDG-PET in clinical oncology: Review and evaluation of results of a private clinical PET-Center, in: Nuclear Medicine Annual 1997 (Freeman LM (ed.) Lippincott/Raven publ., Philadelphia 1997. p. 1-29.
2. Schomburg A, Bender H, Reichel C, et al. Standardized uptake values of Fluorine-18-Fluorodeoxyglucose: The value of different normalization procedures. Eur J Nucl Med 1996;23:571-4.
3. Oehr P, Ruhlmann J, Biersack HJ. FDG-PET in clinical oncology: Review of the literature and report of one institution's experience. J Invest Med 1999;47:452-61.
4. Bender H, Strähler-Pohl HJ, Risse JH, et al. Clinical application of FDG-PET in staging of selected tumors: Experiences and implications, in: Limouris GS, Bender H, Shukla SK, Biersack HJ (eds.) Radionuclides for oncology, Mediterra-Publishers Athens 1998. p. 113-20.
5. Bender H, Kirst J, Palmedo H, et al. Value of 18-Fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. AntiCancer Res 1997;17:1687-92.
6. Ruhlmann J, Schomburg A, Bender H, et al. Fluorodeoxyglucose wholebody positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40:1195-204.
7. 99mTc-Sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
8. Albers P, Bender H, Yilmaz H, et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999;53:808-11.
9. Reske SN, Ackermann R, Baum RP, Biersack HJ, et al. Consensus Onko-PET, Nukle-armedizin 1998;37:45-6.